ENVB (34) IMRN (47) FBLG (36) UPC (33) ⌘ Pro Terminal →

CNS Pharmaceuticals Inc. (CNSP) — RQD Stock Rating Cockpit

$5.00 +4.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.03

CNS Pharmaceuticals Inc. (CNSP) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $7.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNSP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $5.00 (+4.82% 1D, market cap $7.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNSP compare to ENVB and IMRN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNSP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $6.5M) and IMRN (Immuron Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $7.4M). Among the 5-stock peer group, CNSP leads on earnings multiple (N/A) while CNSP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNSP?

▼

Per CNSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729427), CNS Pharmaceuticals Inc. generated $0 in revenue, -$16.0K in net income, and -$13.8M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.03 (+0.68%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY CNSP SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (33% of score)

FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 45 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$5.19-3.9% Next Q

Q2 (-2Q)

Grade D$4.99-7.2% Next Q

Q3 (-1Q)

Grade D$4.63+8% Next Q

Current

Grade D-$5.00-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNSP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNSP currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.31) and Max Pain ($5.25) forces dealer call-delta covering toward $11.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE36% OF RANGE

L: $2$5.00H: $11

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CNSP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

12/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like CNSP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSP)

✓Walkthrough of CNSP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.22%⚡ TESTING RESISTANCE

2026-11-02O $4.51H $5.00L $4.51C $5.00VOL 46.4K

RES: $5.39SUP: $3.53SMA50: $5.31SMA200: $4.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNSP Butterfly Map → + Track CNSP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSP)

Health Care Rank #490 of 1016 ⚔️ ENVB vs CNSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNSP vs. ENVB, IMRN, FBLG, UPC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CNS Pharmaceuticals Inc. (CNSP) ranks #490 by composite RQD confidence (42/100, grade D-) and #921 by equity capitalization ($7.0M). Within this direct 5-issuer industry benchmark cohort, CNSP leads on earnings valuation at N/A trailing P/E, while CNSP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CNSP at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNSP ACTIVE CNS Pharmaceuticals Inc.	D-	42/100	—	—	-35.0%	+4.82%	$7.0M	Benchmark Subject
ENVB Enveric Biosciences Inc.	E	34/100	—	—	-35.0%	-2.06%	$6.5M	/envb-vs-cnsp →
IMRN Immuron Limited	D	47/100	—	—	—	-4.60%	$7.4M	/imrn-vs-cnsp →
FBLG FibroBiologics Inc.	D-	36/100	—	—	-35.0%	+0.21%	$6.3M	/fblg-vs-cnsp →
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-3.25%	$7.7M	/upc-vs-cnsp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729427

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CNS Pharmaceuticals Inc. (CNSP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.0K, operating cash flow of -$13.8M, and free cash flow of -$13.8M (+19.2% YoY). On the balance sheet, CNSP closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$16.0K	-$13.8M	-$13.8M	$8.6M	—
FY2024 (FY)	2024-12-31	$0	-$14.9K	-$17.1M	-$17.1M	$8.7M	—
FY2023 (FY)	2023-12-31	$0	-$18.9K	-$14.1M	-$14.1M	—	—

3. CNSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CNSP compare to ENVB and IMRN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CNSP?

Where is CNSP trading relative to its 50-day, 200-day, and 52-week technical levels?

CNSP last traded at $5.00 (+4.82% on volume of 52,921 shares), positioning the stock -5.84% below its 50-day simple moving average ($5.31) and +9.17% above its 200-day simple moving average ($4.58). Across its 52-week range of $1.90 to $10.54, CNSP sits at the 35.9% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.37 to $5.63).

CNSP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CNSP stock right now?

CNS Pharmaceuticals Inc. (CNSP) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CNSP's 12-month price target and RQD AI Jury consensus?

CNSP's 12-month base price target is $4.64 (range $3.62 to $11.07), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CNSP RQD Cockpit CNSP 12M Forecast CNSP Earnings & Move CNSP Dividends & DRIP CNSP Insiders & 13F CNSP Whale Options CNSP Profit Sankey CNSP News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CNSP — CNS Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CNSP scores 42/100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow scores 7/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 14/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

For a prospective investor, the pillar profile points to weak cash generation as the central issue: the lowest-scoring pillars are tied to returns on capital and insider conviction, and the FCF yield is 0%. The Forensic Balance Sheet pillar is the strongest relative to its maximum, but a Piotroski F-Score of 1/9 signals weak financial-health signals. Upside drivers are not evidenced in the cash-flow data; any thesis would depend on factors outside the provided source data. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data, and the company reports zero revenue in the periods provided.

Business

CNS Pharmaceuticals Inc. (CNSP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is categorized by sector and industry only. Source data does not specify its products, customers, or revenue model. The SEC financials report revenue of $0.0M for each period provided, so the company's commercial revenue generation is not evident in the source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-16.0M	$-0.0M	N/A	$-13.8M	$7.2M	N/A
FY 2024	$0.0M	$-14.9M	$-0.0M	N/A	$-17.1M	$6.5M	N/A
FY 2023	$0.0M	$-18.9M	$-0.0M	N/A	$-14.1M	N/A	N/A

Per the SEC financials, operating losses were reported in each period shown, with net margin, gross margin, and operating margin all listed at 0%. Per the Roarable RQD rating, ROIC is -35% and the Forensic Balance Sheet pillar cites an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5. Reported cash was $7.2M for FY 2025 and $6.5M for FY 2024; debt is listed as N/A across the periods provided.

Recent Catalysts & News Wire Analysis

Recent items in the news wire are all tagged to CNSP and carry a YELLOW light with a "MARKET WIRE" impact label. Headlines reference a stock price forecast, a TradingView estimates page, a kalkine.ca report on strategic pivots among Wednesday's movers, a Yahoo! Finance quote page, a TradingKey market-cap list, and a Yahoo! Finance seasonal-returns chart. The summaries are generic market-coverage descriptions; none of the items in the source data specify a discrete clinical, regulatory, or financing event. The strategic-pivot reference in the kalkine.ca headline is not elaborated in the source data.

Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND with a Macro Tailwind Score of 18/100, a severity score of 94, and a BEARISH direction. The signal reports a 6.00x Net Liquidity beta (r = +0.21) and a True Net Liquidity Index of $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps). Risk watch item: this signal assigns CNSP high sensitivity to liquidity conditions, which in a tightening environment would amplify downside exposure.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and there are no butterfly links. Upstream suppliers and downstream customers are therefore not available in source data. Sector correlation is limited to the liquidity-beta signal described above, which ties CNSP's price sensitivity to net liquidity conditions. Second-order bottlenecks cannot be identified from the provided data. The primary ripple a prospective investor should monitor is the sensitivity of a 6.00x liquidity beta to changes in the Fed-TGA-RRP plumbing, as reflected in the signal's headline and brief.

Open Questions

What products or pipeline assets generate CNSP's business activity, given zero reported revenue across the periods provided?
What is the company's cash runway given FY 2025 cash of $7.2M against FCF of $-13.8M, and how is it being funded?
What is the debt position, since debt is listed as N/A in every reported period?
What does the "strategic pivot" referenced in the kalkine.ca item refer to, and does it alter the operating outlook?
Are there any institutional, insider, or Congressional holders in the holder data, given that the holders section is empty?

CNSP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CNS Pharmaceuticals Inc. (CNSP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNSP Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 7h ago

Cns Pharmaceuticals Stock Price Forecast. Should You Buy CNSP?

StockInvest.us report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 10h ago

CNS Pharmaceuticals, Inc. Estimates – NASDAQ:CNSP

TradingView report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 13h ago

Which Strategic Pivots Are Behind Wednesday's Movers? House of Doge (NASDAQ:HODO), CNS Pharmaceuticals (NASDAQ:CNSP) and More

kalkine.ca report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 16h ago

Ethos Technologies Inc. (LIFE) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 19h ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

Viva Biotech Holdings (VB0.MU) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

HCW Biologics Inc. (HCWB) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNSP Bull vs. Bear Conversation Board — What's Your Call at $5.00?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNSP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.20 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CNSP (D- • RQD 42/100) a Buy at $4.77?

Welcome to the CNSP (CNS Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.63 (-23.9%)

Spot @ $4.77

Pump the brakes on CNSP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CNSP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless CNS Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.58 (+17.0%)

Spot @ $4.77

CNSP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CNSP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.77 (52-wk range $1.90 - $10.54), any beat on forward guidance forces shorts and underweight funds to chase.